<DOC>
	<DOCNO>NCT00855582</DOCNO>
	<brief_summary>Study LVHR Phase 3 study examine efficacy safety tadalafil 2.5 5 mg daily versus placebo treatment erectile dysfunction ( ED ) sign symptoms benign prostatic hyperplasia ( BPH ) men ED sign symptom BPH .</brief_summary>
	<brief_title>A Study Treatment Erectile Dysfunction Benign Prostate Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Have BPH Lower Urinary Tract Symptoms ( LUTS ) base disease diagnostic criterion 1st screening . Have history ED base disease diagnostic criterion 1st screening . Have LUTS Total International Prostate Symptom Score ( IPSS ) great equal 13 2nd screening . Have bladder outlet obstruction define Peak Urine Flow Rate ( Qmax ) great equal 4 less equal 15 milliliter ( mL ) /second ( sec ) ( prevoid total bladder volume assess ultrasound great equal 150 less equal 550 mL minimum void volume 125 mL ) 2nd screening . Make least 4 sexual intercourse attempt 4weeks 2nd screening record Sexual Encounter Profile ( SEP ) diary . Are sexually active adult female partner , expect remain sexually active adult female partner duration study . Agree use approve experimental BPH , overactive bladder ( OAB ) , ED treatment indicate protocol time study . Have take treatment indicate protocol prior 2nd screening . Current treatment nitrate . Prostatespecific antigen ( PSA ) great 10.0 nanogram ( ng ) /mL 1st screening . PSA great equal 4.0 less equal 10.0 ng/mL 1st screen prostate malignancy rule satisfaction urologist . Clinical evidence prostate cancer . Bladder postvoid residual volume ( PVR ) great equal 300 mL ultrasound determination 1st screening . History clinical evidence certain pelvic , bladder , urinary tract , urinary retention condition describe protocol . Lower urinary tract instrumentation ( include prostate biopsy ) within 30 day 1st screening . Clinical evidence severe hepatic impairment 1st screening . Current neurologic disease condition associate neurogenic bladder ( example , Parkinson 's disease multiple sclerosis ) . History significant renal insufficiency define protocol . History ED cause primary sexual disorder include premature ejaculation ED cause untreated endocrine disease . Presence penile deformity judge investigator clinically significant . History certain cardiac cardiovascular condition describe protocol . History resuscitate cardiac arrest . Current treatment certain medication describe protocol . Scheduled plan surgery ( procedure require general , spinal , epidural anesthesia ) course study . History significant central nervous system injury ( include stroke spinal cord injury ) within 6 month 1st screen . Glycosylated hemoglobin ( HbA1c ) great 9 % 1st screening . Prior treatment phosphodiesterase type 5 ( PDE5 ) inhibitor judge investigator ineffective . However , investigator judge subject 's lack response asneeded PDE5 inhibitor result inadequate coordination dose sexual activity treatment , subject may enrol .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
</DOC>